Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency.
van Kampen JJA, Dalm VASH, Fraaij PLA, Oude Munnink BB, Schapendonk CME, Izquierdo-Lara RW, Villabruna N, Ettayebi K, Estes MK, Koopmans MPG, de Graaf M. van Kampen JJA, et al. Among authors: dalm vash. J Infect Dis. 2022 Nov 11;226(10):1781-1789. doi: 10.1093/infdis/jiac085. J Infect Dis. 2022. PMID: 35255136 Free PMC article.
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
Sablerolles RSG, Goorhuis A, GeurtsvanKessel CH, de Vries RD, Huckriede ALW, Koopmans MPG, Lafeber M, Postma DF, van Baarle D, Visser LG, Dalm VASH, Kootstra NA, Rietdijk WJR, van der Kuy PHM. Sablerolles RSG, et al. Among authors: dalm vash. Front Immunol. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319. eCollection 2021. Front Immunol. 2021. PMID: 34691071 Free PMC article. No abstract available.
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: dalm vash. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
Three patients with defects in interferon gamma receptor signaling: A challenging diagnosis.
Zhou Z, Hollink IHIM, Bouman A, Lourens MS, Brooimans RA, van Ham TJ, Fraaij PLA, van Rossum AMC, Zijtregtop EAM, Dik WA, Dalm VASH, van Hagen PM, Ijspeert H, Vermont CL. Zhou Z, et al. Among authors: dalm vash. Pediatr Allergy Immunol. 2022 Apr;33(4):e13768. doi: 10.1111/pai.13768. Pediatr Allergy Immunol. 2022. PMID: 35470942 Free PMC article. No abstract available.
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH; SWITCH Research Group. Sablerolles RSG, et al. Among authors: dalm vash. Clin Infect Dis. 2023 Feb 8;76(3):e533-e536. doi: 10.1093/cid/ciac495. Clin Infect Dis. 2023. PMID: 35723273 Free PMC article.
Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study.
Malahe SRK, Hoek RAS, Dalm VASH, Broers AEC, den Hoed CM, Manintveld OC, Baan CC, van Deuzen CM, Papageorgiou G, Bax HI, Van Kampen JJ, Hellemons ME, Kho MML, de Vries RD, Molenkamp R, Reinders MEJ, Rijnders BJA. Malahe SRK, et al. Among authors: dalm vash. Clin Infect Dis. 2023 Feb 8;76(3):e172-e178. doi: 10.1093/cid/ciac571. Clin Infect Dis. 2023. PMID: 35869843 Free PMC article.
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
Geers D, Sablerolles RSG, van Baarle D, Kootstra NA, Rietdijk WJR, Schmitz KS, Gommers L, Bogers S, Nieuwkoop NJ, van Dijk LLA, van Haren E, Lafeber M, Dalm VASH, Goorhuis A, Postma DF, Visser LG, Huckriede ALW, Sette A, Grifoni A, de Swart RL, Koopmans MPG, van der Kuy PHM, GeurtsvanKessel CH, de Vries RD; SWITCH research group. Geers D, et al. Among authors: dalm vash. iScience. 2023 Jan 20;26(1):105753. doi: 10.1016/j.isci.2022.105753. Epub 2022 Dec 7. iScience. 2023. PMID: 36507223 Free PMC article.
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol.
Tan NH, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, Geers D, Zaeck LM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, van Baarle D, Lafeber M, GeurtsvanKessel CH, de Vries RD, van der Kuy PM. Tan NH, et al. Among authors: dalm vash. Front Immunol. 2022 Nov 29;13:1067749. doi: 10.3389/fimmu.2022.1067749. eCollection 2022. Front Immunol. 2022. PMID: 36524126 Free PMC article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: dalm vash. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
112 results